Virtus ETF Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-425,269
| Closed | -$314K | – | 633 |
|
|
2024
Q4 | $314K | Buy |
425,269
+245,297
| +136% | +$296K | 0.13% | 240 |
|
|
2024
Q3 | $283K | Hold |
179,972
| – | – | 0.13% | 233 |
|
|
2024
Q2 | $302K | Sell |
179,972
-113,120
| -39% | -$203K | 0.15% | 229 |
|
|
2024
Q1 | $703K | Buy |
293,092
+42,169
| +17% | +$90.6K | 0.37% | 133 |
|
|
2023
Q4 | $384K | Buy |
250,923
+129,212
| +106% | +$154K | 0.24% | 174 |
|
|
2023
Q3 | $133K | Sell |
121,711
-15,739
| -11% | -$27.6K | 0.08% | 318 |
|
|
2023
Q2 | $315K | Buy |
+137,450
| New | +$365K | 0.19% | 192 |
|
|
2022
Q2 | – | Sell |
-39,262
| Closed | -$82K | – | 459 |
|
|
2022
Q1 | $82K | Sell |
39,262
-2,322
| -6% | -$6.44K | 0.04% | 334 |
|
|
2021
Q4 | $164K | Sell |
41,584
-2,794
| -6% | -$13.6K | 0.06% | 314 |
|
|
2021
Q3 | $213K | Sell |
44,378
-2,321
| -5% | -$9.53K | 0.09% | 256 |
|
|
2021
Q2 | $214K | Buy |
+46,699
| New | +$225K | 0.09% | 295 |
|
|
2020
Q2 | – | Sell |
-121,070
| Closed | -$236K | – | 476 |
|
|
2020
Q1 | $236K | Sell |
121,070
-10,216
| -8% | -$30.4K | 0.1% | 260 |
|
|
2019
Q4 | $545K | Buy |
131,286
+8,632
| +7% | +$33.2K | 0.09% | 199 |
|
|
2019
Q3 | $369K | Sell |
122,654
-20,618
| -14% | -$63.8K | 0.07% | 191 |
|
|
2019
Q2 | $901K | Buy |
+143,272
| New | +$858K | 0.19% | 152 |
|
|
2019
Q1 | – | Sell |
-82,295
| Closed | -$546K | – | 212 |
|
|
2018
Q4 | $546K | Buy |
82,295
+21,567
| +36% | +$175K | 0.09% | 71 |
|
|
2018
Q3 | $648K | Buy |
60,728
+4,092
| +7% | +$46.9K | 0.07% | 83 |
|
|
2018
Q2 | $680K | Sell |
56,636
-33,209
| -37% | -$340K | 0.6% | 108 |
|
|
2018
Q1 | $770K | Sell |
89,845
-5,234
| -6% | -$48.4K | 0.67% | 79 |
|
|
2017
Q4 | $939K | Buy |
95,079
+75,607
| +388% | +$786K | 1.18% | 36 |
|
|
2017
Q3 | $239K | Buy |
19,472
+1,781
| +10% | +$26.3K | 0.03% | 139 |
|
|
2017
Q2 | $291K | Sell |
17,691
-459
| -3% | -$7.11K | 0.04% | 133 |
|
|
2017
Q1 | $260K | Buy |
18,150
+1,740
| +11% | +$25.8K | 0.05% | 158 |
|
|
2016
Q4 | $227K | Sell |
16,410
-1,239
| -7% | -$19.9K | 0.07% | 161 |
|
|
2016
Q3 | $319K | Hold |
17,649
| – | – | 0.15% | 93 |
|
|
2016
Q2 | $253K | Sell |
17,649
-1,618
| -8% | -$21.9K | 0.19% | 85 |
|
|
2016
Q1 | $230K | Sell |
19,267
-1,219
| -6% | -$12.8K | 0.32% | 68 |
|
|
2015
Q4 | $273K | Buy |
+20,486
| New | +$252K | 0.75% | 53 |
|
Other funds holding LXRX
AG
SL
SSA
Virtus ETF Advisers's LXRX Position: Q1 2025 in Review
Virtus ETF Advisers sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 425,269 shares — an estimated $314K sold.
Virtus ETF Advisers first reported a position in LXRX in Q4 2015 and held it in 28 quarters. The position peaked at $939K in Q4 2017. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.
- Virtus ETF Advisers reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Virtus ETF Advisers sold 425,269 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $314K.
- Virtus ETF Advisers first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 28 quarters.
- Virtus ETF Advisers's Lexicon Pharmaceuticals position peaked at $939K in Q4 2017.
- 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.
Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.